localnews.ie

Merck Sharp & Dohme granted Supreme Court appeal in Clonmel Healthcare patent injunction case

By Aoife Loughran

Historic decision · Decision date:

The Supreme Court will hear the drugmaker's appeal over a refused injunction against a generic version of its Inegy product, the court said on 21 December 2018.

The Supreme Court has granted Merck Sharp & Dohme Corp. leave to appeal in its patent dispute with Clonmel Healthcare Limited, in a determination delivered on 21 December 2018.

Merck Sharp & Dohme asked the Supreme Court to hear an appeal from the Court of Appeal. That court's judgment was delivered on 12 June 2018. The Supreme Court panel was Justice O'Donnell, Justice Charleton and Justice O'Malley.

The case concerns Inegy, a combination drug. The company says it holds patent rights extended by a Supplementary Protection Certificate, which it says protects the product until 1 April 2019. Clonmel launched a generic version of Inegy in April 2018. It is not disputed that the generic version breaches the terms of the patent as extended. Clonmel says the certificate is invalid.

Merck Sharp & Dohme sought an interlocutory injunction, which is a temporary court order made before a full trial. The High Court refused it later that month. The Court of Appeal upheld that decision by a majority. Justice Peart and Justice Whelan formed the majority, and Justice Hogan dissented.

Justice Peart found that damages were an adequate remedy for the drugmaker but not for Clonmel, so the balance of convenience favoured refusing the injunction. Justice Hogan considered that special principles applied where an injunction enforces a property right and where the injunction ruling would effectively decide the case.

The Supreme Court found that the case raises an issue of general public importance. It pointed to a possible difference between the Irish approach and that in England and Wales in patent cases involving generic medicines. It also said the Court of Appeal judgments raise new questions about the test for an interlocutory injunction in intellectual property cases. Clonmel argued that the case did not meet the test for an appeal.

The court noted that the certificate runs only to 1 April 2019 and that a High Court trial was expected in early 2019. It said there is a question about the benefit of deciding the appeal. If Merck Sharp & Dohme says it wants to go ahead, the court will fix a preliminary case management hearing for 15 January 2019. The court also noted delay by the company in completing its books of additional documents.

Sources

Source: Courts Service of Ireland. Read the linked determination for the court’s exact decision.

Request a correction or removal